Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
In development
Reference number: GID-TA11221
Expected publication date: TBC
Following the update about licensing on 11 June, the anticipated publication date for this appraisal has been changed to TBC and will be updated once there is more clarity about when the licence is expected.